CN103069276A - Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒 - Google Patents

Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒 Download PDF

Info

Publication number
CN103069276A
CN103069276A CN2011800327624A CN201180032762A CN103069276A CN 103069276 A CN103069276 A CN 103069276A CN 2011800327624 A CN2011800327624 A CN 2011800327624A CN 201180032762 A CN201180032762 A CN 201180032762A CN 103069276 A CN103069276 A CN 103069276A
Authority
CN
China
Prior art keywords
hmgb1
antibody
disease
aforementioned
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800327624A
Other languages
English (en)
Chinese (zh)
Inventor
S·卡西亚拉
L·斯特纳蒂
R·维塔里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMG Italia SRL
Original Assignee
DMG Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DMG Italia SRL filed Critical DMG Italia SRL
Publication of CN103069276A publication Critical patent/CN103069276A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2011800327624A 2010-08-05 2011-08-01 Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒 Pending CN103069276A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
IT2010A000442 2010-08-05
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Publications (1)

Publication Number Publication Date
CN103069276A true CN103069276A (zh) 2013-04-24

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800327624A Pending CN103069276A (zh) 2010-08-05 2011-08-01 Hmgb1作为炎性肠病病情的生物标志物的用途、其在粪便样品中的非侵入性检测方法及其试剂盒

Country Status (14)

Country Link
US (1) US20130137123A1 (https=)
EP (1) EP2601525A1 (https=)
JP (1) JP2013534313A (https=)
CN (1) CN103069276A (https=)
AU (1) AU2011287193B2 (https=)
BR (1) BR112013002145A2 (https=)
CA (1) CA2807107C (https=)
CL (1) CL2013000223A1 (https=)
EA (1) EA201390197A1 (https=)
IL (1) IL223845A (https=)
IT (1) IT1406051B1 (https=)
MX (1) MX2013001327A (https=)
PE (1) PE20131062A1 (https=)
WO (1) WO2012017466A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
PL3622082T3 (pl) 2017-05-12 2023-07-31 Evonik Operations Gmbh Sposób wykrywania chorób wywołanych przez C. perfringens w stadzie ptaków
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
US12031991B2 (en) * 2018-03-02 2024-07-09 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
DK3894863T3 (en) 2018-12-14 2023-02-20 Evonik Operations Gmbh In vitro-fremgangsmåde til påvisning af aviær intestinal dysbiose
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
HRP20250769T1 (hr) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20060188883A1 (en) * 2003-03-08 2006-08-24 Murray Graeme I Markers for colorectal cancer
CN101132811A (zh) * 2004-10-22 2008-02-27 米迪缪尼股份有限公司 抗hmgb1的高亲和力抗体及其用法
WO2009017444A2 (en) * 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnosis, staging and monitoring of inflammatory bowel disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
US7879553B2 (en) * 2008-03-14 2011-02-01 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US20060188883A1 (en) * 2003-03-08 2006-08-24 Murray Graeme I Markers for colorectal cancer
CN101132811A (zh) * 2004-10-22 2008-02-27 米迪缪尼股份有限公司 抗hmgb1的高亲和力抗体及其用法
WO2009017444A2 (en) * 2007-08-02 2009-02-05 Iss Immune System Stimulation Ab Diagnosis, staging and monitoring of inflammatory bowel disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RYAN M. LEVY ET AL.: "Systemic inflammation and remote organ injury following trauma require HMGB1", 《AM J PHYSIOL REGUL INTEGR COMP PHYSIOL》, vol. 293, 1 October 2007 (2007-10-01), pages 1538 - 1544 *

Also Published As

Publication number Publication date
AU2011287193B2 (en) 2015-08-13
WO2012017466A8 (en) 2013-07-11
EA201390197A1 (ru) 2013-06-28
JP2013534313A (ja) 2013-09-02
AU2011287193A1 (en) 2013-06-13
ITRM20100442A1 (it) 2012-02-06
WO2012017466A1 (en) 2012-02-09
IT1406051B1 (it) 2014-02-06
MX2013001327A (es) 2013-03-08
CA2807107C (en) 2017-01-03
PE20131062A1 (es) 2013-10-16
CL2013000223A1 (es) 2014-03-28
CA2807107A1 (en) 2012-02-09
EP2601525A1 (en) 2013-06-12
BR112013002145A2 (pt) 2016-05-24
US20130137123A1 (en) 2013-05-30
IL223845A (en) 2016-06-30

Similar Documents

Publication Publication Date Title
AU2011287193B2 (en) Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
Roda et al. Crohn’s disease
Liu et al. Inflammatory bowel disease biomarkers
Zollner et al. Faecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2—a comparative study
Sakurai et al. Positioning and usefulness of biomarkers in inflammatory bowel disease
Kaiser et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome
Carroccio et al. Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome
JP2019194600A (ja) 過敏性腸症候群を診断するための経路特異的マーカー
van de Logt et al. S 100 A 12: A noninvasive marker of inflammation in inflammatory bowel disease
Angulo et al. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders
Wędrychowicz et al. Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis
KR20100063052A (ko) 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법
Mori et al. Evaluation of serum calprotectin levels in patients with inflammatory bowel disease
JP2018519499A (ja) 慢性腎疾患の発症のリスクを予測するための方法
Klimczak et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity
Ali et al. Study of albumin, c-reactive protein and calprotectin as non-invasive indicators for the diagnosis and differentiation of inflammatory bowel disease
Huong et al. Role of Calprotectin, IL-6, and CRP in distinguishing between inflammatory bowel disease and diarrhea predominant irritable bowel syndrome
Kaila et al. The Anti‐Saccharomyces Cerevisiae Antibody Assay in a Province‐Wide Practice: Accurate in Identifying Cases of Crohn’s Disease and Predicting Inflammatory Disease
EP4085256A1 (en) Test and in vitro diagnosis of irritable bowel syndrome
Lee et al. Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
Toğrol et al. The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study
KR20130136964A (ko) 창자 감염성 병태의 생물학적 마커로서 hmgb1의 용도, 대변 샘플에서 그의 검출을 위한 비침습적 방법 및 키트
Giulia et al. Crohn’s disease (Primer)
TWI614501B (zh) ５-甲氧基色胺酸作為發炎疾病診斷試劑之用途
Saruta Positioning and Usefulness of Biomarkers in Inflammatory Bowel

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130424